Investigating The Molecular Signature Of ASD Through Integrative Genomics
Funder
National Health and Medical Research Council
Funding Amount
$621,128.00
Summary
Autism is the most severe end of a spectrum of neurodevelopmental conditions, autism spectrum disorders (ASD). We have identified a signature of genes dysregulated in the brain of autistic individuals. The proposed project will investigate how the molecular signature of autism is regulated in the brain, and whether genetic variants in regulatory DNA contribute to the genetic architecture of ASD.
Regulatory RNAs Underlying Genetic Associations With Ankylosing Spondylitis
Funder
National Health and Medical Research Council
Funding Amount
$431,201.00
Summary
Ankylosing spondylitis is a chronic inflammatory disease affecting the spine and causing back pain. The diagnosis of the disease is delayed by up to 10 years due to lack of accurate tests. We aim to identify molecular signatures of the disease that might be used to distinguish inflammatory processes typical of the disease and other causes of back pain. This would allow earlier and more accurate diagnosis of the disease and result earlier patient treatment and better health outcomes.
Discovery And Characterisation Of Long Noncoding RNAs In Human Neurological Disorders
Funder
National Health and Medical Research Council
Funding Amount
$349,647.00
Summary
Numerous regions in our DNA influence how likely we are to develop various diseases, including brain disorders such as Autism and Schizophrenia. However, in many of these regions no genes have been found and they appear “empty”, making it difficult to uncover what’s triggering the disease. This project will use a powerful new technology to discover new genes hidden within these supposedly “empty” regions that are important in brain disorders and investigate how they contribute to disease.
Engineering improved and multifunctional gene editing systems. Advances in genome editing have enabled the targeted modulation of gene expression in cells and provided new tools for biotechnology. This project will combine computational design and genetic selection to deliver the next generation of precision gene editing tools. These new technologies can be used for modification of genes in any cellular compartment and will be useful for understanding and improving energy metabolism. Increased c ....Engineering improved and multifunctional gene editing systems. Advances in genome editing have enabled the targeted modulation of gene expression in cells and provided new tools for biotechnology. This project will combine computational design and genetic selection to deliver the next generation of precision gene editing tools. These new technologies can be used for modification of genes in any cellular compartment and will be useful for understanding and improving energy metabolism. Increased cellular energy production can be harnessed to make valuable biological products, with unprecedented efficiency.Read moreRead less
The characterization of tiny Ribonucleic acids in animal epigenetics. Epigenetics, the inheritance of traits not encoded in deoxyribonucleic acid (DNA), is not well understood in animals. This project will investigate two classes of Ribonucleic acid (RNA) that may form part of an animal-specific epigenetic regulatory system. This study could revolutionize our understanding of animal genetics.
As a molecular geneticist, I am interested in how and why genetic mutations occur, how these changes cause disease or disease predisposition, and ways of better treating and monitoring genetic disease. The ‘model diseases’ I am most interested in are blood cell diseases such as autoimmunity (e.g. arthritis) and leukaemias.
The Identification Of New Epilepsy Genes By Whole Genome Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$1,069,803.00
Summary
Epilepsy is a common brain disorder affecting approximately 50 million people worldwide. The most common type of epilepsy is known as focal epilepsy. Our group has recently shown the importance of genetic mutations as causes of focal epilepsy. Using modern genomic technologies we will identify new genes in focal epilepsy. We will make animal models of these genes to better understand the pathobiology of epilepsy so that new treatments can be developed for patients.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE150100031
Funder
Australian Research Council
Funding Amount
$630,000.00
Summary
PacBio long read sequencer for the Ramaciotti Genomics Consortium of NSW. PacBio long read sequencer for the Ramaciotti Genomics Consortium of New South Wales: This will be one of the first PacBio sequencers for a service facility in Australia. Unlike other next-generation sequencers that have read lengths of 100 to 700 bases, the PacBio long read sequencer generates an average read length of 8,000 bases and a maximum of 20,000 bases. It will be used for research in genomics, metagenomics and tr ....PacBio long read sequencer for the Ramaciotti Genomics Consortium of NSW. PacBio long read sequencer for the Ramaciotti Genomics Consortium of New South Wales: This will be one of the first PacBio sequencers for a service facility in Australia. Unlike other next-generation sequencers that have read lengths of 100 to 700 bases, the PacBio long read sequencer generates an average read length of 8,000 bases and a maximum of 20,000 bases. It will be used for research in genomics, metagenomics and transcriptomics.Read moreRead less
Control Of Genome Regulation And Its Role In Human Disease
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Changes in DNA can lead to differences in susceptibility to developing many diseases. The most common mechanism by which this occurs is through changing when and in which tissues disease-relevant genes get translated into proteins. My research focuses on understanding how DNA changes result in altered gene expression and how this can affect disease susceptibility. This work requires the use of high performance computing and statistical analysis of large genome-scale datasets.
Cellular genomic approach to the pathogenesis of multiple sclerosis. This project compares the levels of gene usage in two important immune cell types between patients with multiple sclerosis and people who do not have the disease. It aims to identify the molecular basis for the disease, in order to identify new diagnostic, preventative and treatment options.